Estimada HelpLine: Cómo viajar durante las vacaciones
Dear HelpLine, I am thinking of traveling to see family this year for the holidays, but this would be the first time taking my wife since she was diagnosed with FTD 2 years ago. Is there anything you can share with me about traveling with someone with FTD? For many people, the holiday season is…
Lee masUna conversación con el vicepresidente de desarrollo clínico de Alector
Earlier this year, the biopharmaceutical company Alector announced that the U.S. Food and Drug Administration (FDA) had granted a “breakthrough therapy designation” to latozinemab, the company’s investigational drug designed to address FTD caused by a variant in the GRN gene. The special designation enables expedited regulatory review of therapies intended to treat serious conditions. A…
Lee masVesper Bio anuncia la finalización exitosa del estudio de fase 1 para el tratamiento potencialmente modificador de la enfermedad para FTD-GRN
Biotechnology company Vesper Bio announced in early September that the phase 1 clinical trial for its potentially disease-modifying treatment for FTD-GRN has successfully concluded. The company noted data from the trial demonstrated excellent safety and tolerability of the orally administered drug VES001. In FTD caused by an inherited GRN mutation, the production of the essential…
Lee mas24 de noviembre de 2024: Reunión y bienvenida en persona en Manchester, NH
Join and learn from others who understand the FTD journey at this in-person AFTD Meet & Greet event, hosted by AFTD Ambassador Shirley Gordon and Kevin Rhodes, co-chair of the AFTD Persons with FTD Advisory Council. The event will take place from 7:30 a.m. – 12:00 p.m. on November 24 at St. Catherine of Siena…
Lee masRecepción en persona en Manchester, NH
Join and learn from others who understand the FTD journey at this in-person AFTD Meet & Greet event, hosted by AFTD Ambassador Shirley Gordon and Kevin Rhodes, co-chair of the AFTD Persons with FTD Advisory Council. RSVP for this event by emailing sgordon@theaftd.org. To learn more, download this flyer.
Lee masAlmuerzo y aprendizaje para cuidadores híbridos de Ohio: demencia frontotemporal
Bring a lunch and join Judy Bearer, ambassador for the Association for Frontotemporal Degeneration, for this lunch and learn event about frontotemporal degeneration (FTD), the most common cause of dementia in adults under 60 (though it can strike adults at any age). We will review possible causes and symptoms, find local resources, and learn how…
Lee masSeminario web de la AFTD: Diagnóstico de la afasia progresiva primaria
With primary progressive aphasia (PPA), problems with language and communication typically deteriorate gradually over time. Initial symptoms are sometimes attributed to anxiety or stress until the ongoing symptoms become disruptive enough to prompt further assessment by a specialist. This webinar is intended for clinicians to support early detection and accurate diagnosis of PPA. Learners will…
Lee masDígale a sus legisladores: reautoricen la financiación de la Ley para los Estadounidenses de Edad Avanzada
You may think that because frontotemporal degeneration strikes many people in the middle of their life, that the Older Americans Act may not apply to you. But the OAA provides funding for services for adult family members and other adults who care for individuals with Alzheimer’s disease and related disorders in their home, regardless of…
Lee masFomentando la esperanza: la AFTD organiza la mesa redonda de investigación de la FTD de 2024
The FTD Research Roundtable is an annual program designed to accelerate FTD drug development by convening various scientific stakeholders to identify common challenges and advance solutions for FTD clinical trials. Biopharmaceutical companies currently conducting FTD pre-clinical and clinical trials are invited to join the FTD Research Roundtable, and in 2024, we were thrilled to have…
Lee masAC Immune y Life Molecular Imaging anuncian la designación de vía rápida de la FDA para el trazador PET Tau
Swiss biopharmaceutical company AC Immune announced in late August that its partner, German biopharmaceutical company Life Molecular Imaging (LMI), received a Fast Track Designation from the US Food and Drug Administration (FDA) for a Tau PET tracer. PET, or positron emission tomography, is a form of medical imaging that uses a radioactive tracer to visualize…
Lee mas
Spanish (Mexico) 
English 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)